Abstract
Violation of the proportional-hazards (PH) assumption may lead to an underestimation of treatment effects when conventional therapies are compared to immunotherapies. When the PH assumption was violated, several health technology assessments in the UK for drugs in non-small cell lung cancer (NSCLC) used complex indirect treatment comparison (ITC) models to demonstrate treatment benefits. The purpose of this review is to describe how such ITC methodologies have evolved over time in tandem with drug innovation, as well as to assess how well complex models were accepted by Evidence Review Groups (ERG).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
